P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

• Shaun Fleming,
• Gail Roboz,
• Amir T. Fathi,
• Tian Y. Zhang,
• Andrew Wei,
• Hetty Carraway,
• Leanne Holes,
• Erica Petrlik,
• Thomas Prebet,
• Daniel Lopes De Menezes,
• Iryna Bluemmert,
• Hao Sun,
• Farhad Ravandi

Affiliations

Shaun Fleming

1 Alfred Hospital, Melbourne, Victoria, Australia

Gail Roboz

2 Weill Cornell Medicine, New York, NY, United States

Amir T. Fathi

3 Massachusetts General Hospital, Boston, MA, United States

Tian Y. Zhang

4 Stanford University School of Medicine, Stanford, CA, United States

Andrew Wei

5 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia

Hetty Carraway

6 Cleveland Clinic, Cleveland, OH, United States

Leanne Holes

7 Bristol Myers Squibb, Princeton, NJ, United States

Erica Petrlik

7 Bristol Myers Squibb, Princeton, NJ, United States

Thomas Prebet

8 Bristol Myers Squibb, Summit, NJ, United States

Daniel Lopes De Menezes

9 Bristol Myers Squibb, San Francisco, CA, United States

Iryna Bluemmert

10 Bristol Myers Squibb, Boudry, Switzerland

Hao Sun

8 Bristol Myers Squibb, Summit, NJ, United States

Farhad Ravandi

11 MD Anderson Cancer Center, Houston, TX, United States